Schizophrenia and Physical Health: Metabolic and Cardiovascular Risks
Author: Ukrainian Psychological Hub · Published: October 9, 2026 · Editorial Policy
Schizophrenia affects physical health as well as mental health. People living with schizophrenia experience higher rates of cardiovascular disease and cardiometabolic risk factors, including smoking, weight gain, abnormal cholesterol levels, insulin resistance, and type 2 diabetes. These risks reflect interacting influences: social disadvantage and unequal access to medical care, nutrition and physical activity, underlying vulnerability, coexisting health conditions, and the metabolic effects of some antipsychotic medications. Each influence warrants assessment and practical treatment.
Physical-health monitoring should begin when schizophrenia or a related psychotic disorder is first evaluated and continue throughout care. The strongest clinical guidance calls for baseline measurements, early follow-up after antipsychotic initiation, regular review of blood pressure and metabolic blood tests, and prompt treatment of conditions identified. WHO physical-health guidance and NICE schizophrenia recommendations provide detailed frameworks. This article explains what the risks are, when they can appear, how they are measured, and which preventive and clinical interventions have meaningful evidence.
Key Points
The main physical-health risks associated with schizophrenia include cardiovascular disease, obesity, type 2 diabetes, dyslipidemia, hypertension, and tobacco-related illness. Their importance is established by large epidemiologic datasets, systematic reviews, and clinical guidelines. An individual's outcomes depend on actual health measurements, medications, access to effective care, and many other factors.
Metabolic problems can begin near a first episode of psychosis, including before prolonged medication exposure. Different antipsychotics have substantially different average metabolic effects. Monitoring weight alone is insufficient because diabetes, abnormal lipids, and cardiovascular risks also require assessment. The appropriate response is integrated medical and psychiatric care, undertaken through shared decisions rather than abrupt self-directed treatment changes.
Why Does Physical Health Matter in Schizophrenia?
Schizophrenia is a clinical disorder characterized by disturbances that can include delusions, hallucinations, disorganized thinking or behavior, negative symptoms, and cognitive difficulties. Diagnosis requires a professional evaluation over time; individual symptoms or a screening result do not establish schizophrenia. For the psychiatric description, see our comprehensive schizophrenia guide. This article addresses a separate question: the physical illnesses and preventable health risks that often coexist with that diagnosis.
Life-expectancy statistics illustrate the population-level health gap, but they must be interpreted with care. The World Health Organization reports that adults with severe mental disorders experience substantial excess premature mortality, much of it associated with physical illnesses. U.S. National Institute of Mental Health data describe an estimated 28.5 potential years of life lost among people with schizophrenia in one U.S. analysis, with conditions such as heart disease, liver disease, and diabetes contributing to premature death. These figures summarize groups in particular settings and periods; they do not predict how long a particular person will live.
Cardiovascular disease matters because changes in blood pressure, blood sugar, circulating lipids, vascular health, and tobacco exposure can accumulate before symptoms appear. A person may feel reasonably well while treatable risk factors remain undetected. The problem therefore includes both the higher prevalence of risk factors and missed opportunities for preventive care. The 2025 systematic review of cardiovascular and psychiatric guidelines reinforces the need for better coordination across specialties.
What Are the Main Metabolic and Cardiovascular Risks?
Weight gain and abdominal adiposity
An increase in body weight is a visible and often distressing change during treatment, especially after some antipsychotics are started. Abdominal fat accumulation is relevant to insulin resistance, blood pressure, and lipid abnormalities. Body mass index (BMI) provides a broad weight-for-height measure, while waist circumference adds information about central adiposity. Neither number by itself gives a complete assessment of cardiovascular health.
Rapid weight gain can affect comfort, mobility, body image, sleep, social participation, and treatment preferences. A clinical discussion should treat these effects as legitimate outcomes of care. Early weight trajectories are especially important because a gradual annual check may overlook substantial changes over the first weeks. The NICE monitoring schedule gives specific early measurement intervals.
Insulin resistance, prediabetes, and type 2 diabetes
Insulin resistance means that cells respond less effectively to insulin, which may lead to increased blood glucose and eventually prediabetes or type 2 diabetes in some people. Some antipsychotic drugs can affect weight, appetite, glucose regulation, and insulin sensitivity. Sedentary behavior, poor sleep, family history, age, and existing metabolic disease also influence risk. A person can have elevated glucose with little or no weight gain, so weighing the person does not replace laboratory testing.
Clinicians typically use fasting plasma glucose or hemoglobin A1c (HbA1c) as part of metabolic assessment, applying established diagnostic thresholds and confirming abnormal findings when clinically indicated. HbA1c reflects average blood sugar over roughly two to three months; fasting glucose provides a measurement at a particular point in time. Interpretation may be affected by some medical conditions, which clinicians consider when choosing or repeating tests. NICE explicitly includes fasting glucose or HbA1c at baseline and during follow-up.
Dyslipidemia and cardiovascular disease
Dyslipidemia means unhealthy levels of blood lipids, which may include elevated LDL cholesterol, elevated triglycerides, or reduced HDL cholesterol. These findings contribute to long-term atherosclerotic disease risk. Cardiovascular outcomes include coronary artery disease, heart attack, stroke, heart failure, and other vascular conditions. Their causes are multifactorial; schizophrenia-related risk is not reducible to a single medication effect.
Blood pressure, nicotine exposure, diabetes, kidney function, age, family history, and lipid profile inform a clinician's assessment. U.S. cardiovascular prevention tools, including the American Heart Association PREVENT equations, support structured discussions, but their numerical estimates should be contextualized for people with schizophrenia, whose additional risks and healthcare access may not be fully represented in every generic calculator.
Metabolic syndrome
Metabolic syndrome is a clinical grouping of interconnected cardiovascular and metabolic risk factors, commonly involving abdominal obesity, elevated blood pressure, high triglycerides, low HDL cholesterol, and elevated blood glucose. Depending on the accepted definition, meeting a specified combination of these measures establishes the syndrome; having schizophrenia by itself does not. Metabolic syndrome signals the need to address multiple modifiable risks together rather than treating an isolated measurement as the whole problem.
Thresholds differ between diagnostic frameworks, and some waist circumference thresholds depend on population characteristics. For research comparisons, these differences affect reported prevalence. In its synthesis of first-episode psychosis studies, Zierotin and colleagues (2026) explicitly describe the variation in metabolic syndrome definitions across included cohorts.
Other physical health problems
Cardiometabolic conditions are the main focus here, but people living with schizophrenia also need ordinary preventive care for respiratory disease, dental problems, infections, liver and kidney conditions, sleep disorders, and cancer screening as appropriate to age and personal history. A complete health plan includes immunizations, sexual and reproductive health, screening examinations, and treatment of acute medical complaints. Pain, fatigue, or shortness of breath warrants a medical assessment based on the symptoms, rather than being attributed automatically to psychiatric illness. The WHO guidance treats physical comorbidity as a core part of severe mental disorder care.
When Do Cardiometabolic Changes Begin? Evidence From First-Episode Psychosis
Risk assessment should start early. A 2026 systematic review and meta-analysis by Zierotin and colleagues synthesized 82 studies of first-episode psychosis, including cohorts with no more than 28 days of antipsychotic exposure at baseline. In pooled samples, obesity prevalence was estimated at 5.4% at baseline and 26.6% at one to three years; metabolic syndrome was estimated at 8.5% and 18.2% at those respective time points. The review also reported an average weight increase of approximately 2.5 kilograms at four to eight weeks and 13.4 kilograms beyond five years in the included follow-up data.
These findings demonstrate why assessment should not be postponed until years of treatment have passed. They also have important limitations: different studies assessed different populations and time windows, statistical heterogeneity was often high, and medication exposure after baseline was incompletely quantified. The pooled changes cannot be interpreted as the effect of a single drug, as a rate for every newly diagnosed patient, or as a personal forecast. More detailed information about early psychosis is available in our first-episode psychosis guide and coordinated specialty care article.
A separate 2026 systematic review of peripheral organ-system findings in drug-naïve first-episode mental illness adds evidence that some physiological differences can already be observed early in illness. Such observational comparisons support early screening; they do not prove that schizophrenia alone directly causes a particular metabolic disease.
Why Are the Risks Higher? A Multilevel Explanation
Medication-related metabolic effects
Antipsychotic medications are central treatments for many people with schizophrenia and can substantially reduce psychotic symptoms and relapse risk. Different agents can also influence appetite, energy balance, glucose, lipids, and weight. Medication choice should therefore account for both the psychiatric benefit and the full adverse-effect profile, including movement symptoms, sedation, sexual effects, prolactin, heart rhythm effects, and metabolic changes. The choice belongs to shared clinical decision-making. See antipsychotics for schizophrenia for the fuller treatment discussion.
In a large network meta-analysis of 18 antipsychotics in acute schizophrenia treatment, olanzapine and clozapine had less favorable average metabolic profiles, while agents including aripiprazole, lurasidone, and ziprasidone showed smaller metabolic changes on the outcomes studied. These rankings describe average differences across trials, often relatively short in duration, and do not guarantee an individual response. They should not be converted into a patient-led switch or discontinuation rule.
Clozapine remains an important treatment for treatment-resistant schizophrenia despite its considerable metabolic and other medical monitoring requirements. Decisions about clozapine also consider serious risks beyond metabolism and its potential clinical benefits. Those issues are discussed in our treatment-resistant schizophrenia and clozapine guide.
Smoking and nicotine exposure
Tobacco smoking raises the risk of cardiovascular and respiratory disease, malignancy, and premature death. Smoking-related health risks and barriers to cessation deserve routine, nonjudgmental attention in schizophrenia care. Treatment may include behavioral support and evidence-based medications selected with a healthcare professional. Relapse into smoking is a reason to adjust the support plan, not to abandon further attempts.
A clinically important medication interaction is often missed: tobacco smoke, rather than nicotine alone, induces drug-metabolizing pathways that affect clozapine and olanzapine concentrations. When a person stops or substantially changes cigarette smoking, prescribers may need to reassess levels, adverse effects, and dosing. Changes should be communicated promptly to the prescribing team; NICE specifically flags this interaction. Vaping or using nicotine-replacement products does not reproduce all the enzyme-inducing effects of combustible smoke.
Physical activity, nutrition, sleep, and environmental constraints
Sedation, low motivation, cognitive difficulties, pain, disrupted routines, low income, limited access to safe exercise spaces, food insecurity, and fragmented services can all make health maintenance harder. These are practical barriers to plan for, not evidence that the person lacks interest in health. Symptoms and treatment effects may interact with each other: daytime sedation may reduce activity; reduced activity may contribute to deconditioning; poor sleep may complicate metabolic control and daily functioning.
Interventions work best when adapted to the person's functional needs, resources, and priorities. Walking with support, accessible group exercise, nutritious low-cost meals, structured activity scheduling, and practical assistance attending appointments can be more realistic than a demanding program that cannot be sustained. A 2024 systematic review and meta-analysis of exercise for psychotic disorders describes potential benefits as well as variation across exercise studies.
Healthcare-system gaps and diagnostic overshadowing
Diagnostic overshadowing occurs when a physical complaint is discounted or explained away because a person has a psychiatric diagnosis. Cardiometabolic monitoring can also fall through gaps between primary care and specialty mental-health services. The result may be delayed diabetes diagnosis, undertreated hypertension, missed lipid abnormalities, or incomplete follow-up after blood tests. These are care-system responsibilities, not shortcomings of the patient.
Clinical guidelines call for clear ownership of each test and each abnormal result. According to NICE the specialty team maintains responsibility for physical-health and antipsychotic monitoring for at least the first 12 months, or longer until stabilization, with coordinated transfer to primary care thereafter. U.S. arrangements vary by insurance, service design, and local resources, so the practical principle is to name the clinician or team responsible for results and follow-up.
What Physical-Health Tests and Measurements Are Recommended?
Assessment schedules are based on the patient's medical history, drug regimen, age, risk factors, and the clinical guideline used. The following evidence-based outline closely follows NICE CG178 and its physical-health quality standard. It is an illustration of one major guideline, not a substitute for local prescribing protocols or more frequent monitoring when symptoms or abnormal results require it.
Before starting an antipsychotic
A baseline assessment ordinarily documents weight, BMI where appropriate, waist circumference, pulse and blood pressure, fasting glucose or HbA1c, blood lipid profile, diet, activity, smoking status, and relevant medical and family history. NICE also includes prolactin and movement-disorder assessment in its antipsychotic baseline recommendations. The clinician may order additional investigations based on symptoms or medication-specific requirements. An ECG is appropriate when specified by the medicine's product information, relevant cardiovascular risk or history exists, or particular inpatient circumstances apply.
During the first weeks and months
NICE recommends measuring weight weekly during the first six weeks of antipsychotic treatment, again at 12 weeks, at one year, and annually thereafter. It recommends pulse and blood pressure at 12 weeks, one year, and annually, with glucose or HbA1c and lipids checked at 12 weeks, one year, and annually. More frequent follow-up may be appropriate after rapid weight change, abnormal measurements, high-risk medication exposure, or emerging symptoms. Clinicians and patients should also discuss sedation, activity, diet, adverse effects, and other problems as treatment progresses.
At least annually over the longer term
Long-term monitoring covers weight, waist circumference, blood pressure, pulse, glucose status, lipids, smoking, physical activity, and general health. Preventive screenings and treatment for established diabetes, hypertension, or cardiovascular disease follow the relevant general medical standards. Results must be reviewed and acted on: an abnormal A1c or lipid panel is a clinical finding requiring interpretation and a plan, not simply a number to record.
For a person already diagnosed with diabetes, heart disease, or kidney disease, follow-up should reflect the condition-specific standard of care, which may be more frequent or broader than annual schizophrenia monitoring. A normal previous test does not make future testing unnecessary. The WHO physical health recommendations support integrated medical and psychiatric management.
How Can Cardiovascular and Metabolic Risk Be Reduced?
Treat identified cardiovascular risks with standard medical care
Hypertension, diabetes, and dyslipidemia have established medical treatments. Management may include blood pressure medication, lipid-lowering treatment, diabetes care, smoking cessation, and individualized lifestyle support, depending on the findings and the person's overall risk. Schizophrenia is a reason to strengthen access and coordination, not to withhold ordinary evidence-based cardiovascular medicine. The 2025 cross-disciplinary guideline review documents a continuing need for consistent integration.
Risk calculators can assist treatment discussions. The AHA PREVENT framework considers cardiovascular, kidney, and metabolic health, but clinicians must still apply judgment, especially when there are risk factors or population characteristics that prediction equations may incompletely capture. Prescribing decisions depend on age, values, comorbidity, specific risk estimates, and current cardiovascular recommendations.
Build sustainable nutrition and activity support
Nutrition support can prioritize accessible meals, balanced eating patterns, adequate protein and fiber, reduced excess sugary drinks, and changes compatible with the person's budget and cultural preferences. A registered dietitian may be helpful when available. Physical activity can be introduced gradually and adapted for current fitness, mobility, medication effects, medical conditions, and safety. Exercise programs should be designed collaboratively so the plan remains feasible in daily life.
Research supports structured lifestyle programs, but results are heterogeneous. Studies differ in intensity, staffing, attendance, follow-up, and outcomes measured. Some interventions improve weight or metabolic markers modestly; others show little sustained change. A program that provides reminders, transport, social support, accessible scheduling, and follow-up may reduce barriers more effectively than generic advice alone. NICE recommends offering combined healthy eating and physical activity support.
Review medication choices without compromising psychiatric stability
If significant weight gain, elevated glucose, or abnormal lipids occur, a clinician may review the antipsychotic's dose, choice, benefits, other adverse effects, and alternatives. Switching to a drug with lower average metabolic burden may be reasonable in selected circumstances, while a stable regimen may have major relapse-prevention benefits. Decisions require careful individualized assessment, monitoring, and follow-up. Suddenly stopping an antipsychotic can increase the risk of relapse and should not be used as a weight-management strategy.
A person should be able to discuss the personal importance of weight, energy, metabolic health, sleep, and sexual health alongside symptom control. Shared decision-making can improve the match between a treatment plan and the outcomes the person values. The American Psychiatric Association schizophrenia practice guideline and NICE emphasize a coordinated, individualized treatment approach.
Metformin and other medication-based strategies
Metformin has been studied for preventing and managing antipsychotic-associated weight gain and related metabolic changes. A 2025 consensus-validated guideline for metformin prevention offers specific situations in which clinicians can consider co-prescribing it for people initiating antipsychotics. The evidence is strongest for weight-related outcomes in selected populations; metformin is a prescription drug requiring consideration of kidney function, gastrointestinal tolerability, other conditions, interactions, and ongoing monitoring. It should not be treated as a universal supplement or started without medical evaluation.
Newer anti-obesity and diabetes treatments, including glucagon-like peptide-1 receptor agonists, are being investigated and used in some eligible people with severe mental illness. The degree of evidence depends on the specific agent, population, clinical indication, and outcome, and studies of weight reduction should not automatically be interpreted as proof of fewer future cardiovascular events in schizophrenia. Individualized obesity or diabetes treatment belongs with clinicians who can evaluate established indications, adverse effects, cost, availability, and psychiatric medication interactions.
Coordinate smoking cessation with psychiatric prescribing
Smoking cessation can reduce long-term health risk, and the process should include practical support for withdrawal, stress, and recurrence. For people taking clozapine or olanzapine, advance communication about changing combustible tobacco use is especially important because the prescribing clinician may need closer follow-up. Relevant monitoring and any medication adjustment are medical decisions. NICE's schizophrenia guideline sets out the interaction warning and clinical follow-up principles.
Who Is Responsible for Physical-Health Monitoring?
A reliable plan identifies a primary care clinician for general medical needs and a mental-health prescriber or team for treatment-specific monitoring. Responsibilities may overlap, so written coordination is useful. The plan should name who orders blood tests, who receives results, who tells the patient what those results mean, who initiates treatment for abnormalities, and who checks that recommended follow-up actually occurred. A missed result is a system failure that should be resolved, even when the patient feels well.
Care coordinators, nurses, pharmacists, family physicians, psychiatrists, dietitians, and social workers may each contribute. With the patient's consent, family members or trusted supporters can help track appointments or organize transportation. Respectful communication and accessible explanations support engagement. Coordinated specialty care is one model for integrating needs earlier in the course of psychosis.
A Practical Physical-Health Conversation With Your Care Team
At an appointment, it can help to ask: What are my current weight trend, blood pressure, glucose or HbA1c, and cholesterol results? When were they last measured, and when should they be repeated? Does my medication have meaningful metabolic or heart-rhythm risks? If a result is abnormal, who will manage it? What changes can we make that support both psychiatric stability and physical well-being? What should I do if I start or stop smoking? Which preventive screenings am I due for? These questions turn general advice into an accountable care plan.
Keeping a simple record of medications, smoking status, recent laboratory results, weight trends, symptoms, and appointments can reduce fragmentation. A person may choose to involve a supporter, particularly during periods of cognitive difficulty or illness recurrence. The plan can be reviewed as circumstances change. Long-term outcomes involve physical functioning, self-determination, social connection, and access to care as well as psychotic symptoms; see recovery and long-term care.
When Is Medical Assessment Urgent?
Symptoms such as new chest pain or pressure, severe unexplained shortness of breath, sudden one-sided weakness, new trouble speaking, fainting with concerning symptoms, or other signs of possible heart attack or stroke require urgent emergency assessment. Rapid deterioration, severe dehydration, marked confusion, or signs of serious medication reactions also warrant prompt clinical evaluation. These symptoms should never be dismissed because the person has schizophrenia.
People taking clozapine who develop chest pain, breathlessness, persistent unexplained rapid heartbeat, fever, or profound fatigue need urgent assessment because clinicians must consider myocarditis and other serious causes. The article on clozapine and treatment-resistant schizophrenia provides condition-specific context. Severe mental distress or acute psychiatric safety concerns also require appropriate crisis assessment, but their management remains distinct from this article's cardiometabolic focus.
Frequently Asked Questions
Does schizophrenia directly cause heart disease?
Schizophrenia is associated with elevated cardiovascular risk, but heart disease usually reflects interacting contributors such as smoking, metabolic abnormalities, underlying vulnerability, social factors, medication effects, and access to medical care. An association does not establish a single direct cause in an individual. Assessment should identify which risk factors are present and treat them appropriately.
Can someone with schizophrenia have normal physical health?
Yes. Schizophrenia does not determine an individual's laboratory results, cardiovascular history, fitness, or future health. Population-level risks justify prevention and monitoring, while individual care is guided by actual measurements, history, and choices.
Which antipsychotics are most likely to cause weight gain?
Average metabolic effects differ substantially across antipsychotics. In the Pillinger and colleagues network meta-analysis olanzapine and clozapine were among the drugs with the least favorable metabolic profiles. Any person's response can differ from the study average, and medication selection must also consider psychiatric benefit and other safety considerations.
Can blood sugar become abnormal without major weight gain?
Yes. Weight trends provide useful information, but they do not measure insulin sensitivity or diagnose diabetes. This is why clinical guidance includes glucose or HbA1c testing even when there has been little noticeable weight change.
How often should metabolic blood tests be done?
A commonly used NICE schedule includes baseline glucose or HbA1c and lipids, repeat testing at 12 weeks, again at one year, and then at least annually. Individual circumstances can justify earlier or more frequent testing. Local standards and medication-specific guidance may differ.
Should someone stop an antipsychotic after gaining weight?
Weight gain should prompt timely discussion and evaluation, not abrupt medication discontinuation. Clinicians can assess whether nutrition and activity support, treatment of metabolic abnormalities, metformin in selected cases, or a carefully planned medication adjustment is appropriate. Any change needs a psychiatric relapse-prevention plan.
Can exercise improve health in schizophrenia?
Exercise can improve fitness and may benefit selected symptoms and metabolic outcomes, but study results vary by program and outcome. A personally feasible, supported exercise plan is more useful than a uniform prescription. Exercise reviews and clinical guidance support integrating activity with broader care.
Does a normal ECG rule out cardiovascular risk?
No. An electrocardiogram assesses aspects of cardiac electrical activity at a particular time. It does not replace blood pressure measurement, lipid testing, diabetes evaluation, or assessment of smoking and other atherosclerotic risk factors. Clinicians order ECGs for specific indications, including medication-related rhythm concerns.
Why does quitting smoking matter if a person takes clozapine?
Quitting combustible tobacco reduces major long-term health risks, but it can also change how the body metabolizes clozapine. Inform the prescribing team before a planned change and promptly after an unplanned one, so the clinician can arrange appropriate monitoring.
Who should order and interpret the tests?
The answer depends on the care setting, but responsibilities must be explicit. During antipsychotic initiation, mental-health prescribing teams commonly oversee monitoring; long-term care often requires coordinated primary care. The relevant clinician should explain abnormal results, arrange follow-up, and document the plan.
Conclusion
Physical-health care is an integral part of schizophrenia care. Cardiometabolic risk can emerge early, progress silently, and respond to timely monitoring and treatment. The most useful approach combines psychiatric stability, preventive medical care, realistic nutrition and activity support, tobacco treatment, and coordinated management of blood pressure, glucose, weight, and lipids. Individual prognosis develops through concrete clinical circumstances and care over time.
Related Articles
Schizophrenia: Symptoms, Causes, Diagnosis, Treatment, and Recovery — The main clinical overview and starting point for the EN-03 cluster.
Antipsychotics for Schizophrenia: Benefits, Side Effects, and Monitoring — Medication-specific benefits, harms, and shared prescribing decisions.
Schizophrenia Treatment: Medication, Therapy, and Coordinated Care — How multidisciplinary treatment is organized.
First-Episode Psychosis: Early Signs, Assessment, Treatment, and Recovery — Earlier clinical pathways, including the period when cardiometabolic risks first need attention.
Can You Recover From Schizophrenia? Outcomes and Long-Term Care — Recovery as a multidimensional long-term process.
References
American Heart Association. (2023). Predicting Risk of cardiovascular disease EVENTs (PREVENT) calculator. Official AHA resource.
American Psychiatric Association. (2020). The APA Practice Guideline for the Treatment of Patients With Schizophrenia. APA practice guideline.
Ang, J. E., Xu, Y., Cropley, V., et al. (2026). Altered function of peripheral organ systems in first-episode drug naïve mental illnesses: A systematic review and meta-analysis. Molecular Psychiatry. doi:10.1038/s41380-026-03891-y.
Carolan, A., Hynes-Ryan, C., Agarwal, S. M., et al. (2025). Metformin for the prevention of antipsychotic-induced weight gain: Guideline development and consensus validation. Schizophrenia Bulletin, 51(5), 1193–1205. doi:10.1093/schbul/sbae205.
Cooper, S. J., Reynolds, G. P., et al. (2016). BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. Journal of Psychopharmacology, 30(8), 717–748. doi:10.1177/0269881116645254.
Delli Colli, M., Greenway, K. T., & Goldfarb, M. (2025). Cross-disciplinary cardiovascular and psychiatric recommendations: A systematic review of clinical guidelines. The International Journal of Psychiatry in Medicine. doi:10.1177/00912174251348996.
National Institute for Health and Care Excellence. (2014; updated). Psychosis and schizophrenia in adults: Prevention and management (CG178). NICE guidance.
National Institute for Health and Care Excellence. (2015; updated). Quality statement 6: Assessing physical health (QS80). NICE quality standard.
National Institute of Mental Health. (n.d.). Schizophrenia: Statistics and burden. NIMH statistics.
Pillinger, T., McCutcheon, R. A., Vano, L., et al. (2020). Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia: A systematic review and network meta-analysis. The Lancet Psychiatry, 7(1), 64–77. doi:10.1016/S2215-0366(19)30416-X.
Rißmayer, M., Kambeitz, J., Javelle, F., & Lichtenstein, T. K. (2024). Systematic review and meta-analysis of exercise interventions for psychotic disorders: The impact of exercise intensity, mindfulness components, and other moderators on symptoms, functioning, and cardiometabolic health. Schizophrenia Bulletin, 50(3), 615–630. doi:10.1093/schbul/sbae015.
World Health Organization. (2018). Management of physical health conditions in adults with severe mental disorders: WHO guidelines. WHO publication.
Zierotin, A., Murphy, J., Stano, A., et al. (2026). Short-, medium-, and long-term cardiometabolic outcomes in first-episode psychosis: A systematic review and meta-analysis. Schizophrenia Bulletin, 52(2), sbag008. doi:10.1093/schbul/sbag008.